On 26 August 2026 a University of Oxford team reported in Nature Medicine that the recombinant shingles vaccine now in wide use is associated with less heart disease than the live vaccine it replaced. They compared 36,460 U.S. adults aged 60 and over vaccinated in April–September 2018, when 93.5 percent received the recombinant shot (Shingrix), with 36,460 matched people vaccinated in the same months of 2017, when 98.6 percent received the live attenuated shot (Zostavax). Over seven years the recombinant group had a 9 percent lower cardiovascular burden: restricted mean time lost ratio 0.91 (95% CI 0.88–0.95).
This is not a randomized trial. It does not compare vaccinated people with people who skipped the shot. The authors say the result justifies trials, not a new indication. The association was strongest in the first 3.5 years and then faded.
Shingles is the painful reactivation of latent varicella-zoster, the chickenpox virus. Shingrix replaced Zostavax in the United States after October 2017 because it prevents shingles better. Heart disease is a separate question. Earlier papers had compared people who chose a vaccine with people who did not, which is an easy way to mix in a “healthy vaccinee” bias. Oxford used the switchover itself as a natural experiment: both groups had chosen to be vaccinated.
Why it matters
Cardiovascular disease is still the leading cause of death in the United States. The paper’s own translation: if a 0.8 percent absolute difference in cumulative ischemic heart disease and heart failure among adults over 60 were confirmed in trials, that would be hundreds of thousands of cases in the U.S. alone. Maxime Taquet, who led the study, put the same thought in the Oxford Health BRC note: vaccinating older adults against shingles could, if the signal is real, protect the heart as well as the skin and — from this group’s earlier paper — the brain.
The hedge belongs next to that sentence. The E value is 1.42. An unmeasured confounder 1.42 times more common in the 2017 cohort, and 1.42-fold associated with worse heart outcomes after matching, could wipe the finding out. Taquet has taken consultancy fees from GSK, which makes Shingrix; co-author John A. Todd is a GSK consultant. The paper says GSK had no involvement and did not know about the study until it was accepted.
The print
Primary endpoint: first diagnosis of ischemic heart disease, ischemic stroke or heart failure, from day 1 to seven years after vaccination. Data: TriNetX U.S. Collaborative Network.
| Outcome, 7 years | Recombinant-era vs live-era |
|---|---|
| Composite CVD burden (RMTL ratio) | 0.91 (0.88–0.95) — 9% less time lived with a diagnosis |
| Ischemic heart disease | 10% less burden, 0.90 (0.87–0.94) |
| Heart failure | 12% less, 0.88 (0.83–0.93) |
| Ischemic stroke, men | 12% less, 0.88 (0.78–0.98) |
| Atrial fibrillation | 7% less, 0.93 (0.88–0.98) |
| n, each arm | 36,460 |
| Share recombinant in 2018 arm | 93.5% |
| Share live in 2017 arm | 98.6% |
| Absolute IHD / heart-failure difference | 0.8% in cumulative incidence |
No significant association with myocarditis, peripheral arterial disease, hemorrhagic stroke or transient ischemic attack. STEMI moved in the same direction as ischemic heart disease but did not reach significance. A TDaP-vaccine control in the same calendar windows showed no period effect on heart outcomes (RMTL ratio 1.01, 0.99–1.03). A negative-control bundle of painful acute conditions was also null. Shingles itself, the positive control, was lower in the recombinant arm, as expected.
Sex: the composite held in women (20,056 per arm) and men (16,300 per arm). Stroke was the exception — the male-only finding.
How they did it
The U.S. switch from Zostavax to Shingrix in October 2017 created two vaccinated cohorts a year apart. Oxford matched on 83 covariates, including age in two-year bins, sex, race, ethnicity, a stack of diagnoses, prior herpes, influenza vaccination and heart drugs. They used restricted mean time lost rather than a single hazard ratio because they expected the proportional-hazards assumption to fail over seven years.
First authors are Fabiana Corsi-Zuelli and colleagues in Oxford psychiatry; Taquet and Paul Harrison are corresponding authors. Funding: NIHR Oxford Health Biomedical Research Centre and others. The same group reported in 2024 that recombinant shingles vaccination was associated with lower dementia risk, using a similar design.
They argue the heart signal is probably not just “fewer shingles cases.” The absolute difference in shingles by mid-follow-up was under 0.5 percent, against about 1.5 percent less ischemic heart disease. Protection also showed up early, which is the wrong shape for a slow accumulation of prevented shingles. A previous natural experiment of live vaccine versus no vaccine did not cut heart disease or stroke. A more plausible path, they write, is the AS01 adjuvant reprogramming monocytes, including lower IL-6 responses — and IL-6 inhibition is already tied to lower cardiac risk.
What this is not
It is not a new FDA indication. It is not proof that Shingrix prevents heart attacks. It is not a comparison with being unvaccinated; if the live vaccine itself has some cardiac benefit, Oxford’s contrast understates the recombinant shot. They could not study booster doses inside this design. Diagnoses are EHR codes, not adjudicated events. Unmeasured income, smoking and diet could still differ between the 2017 and 2018 vaccinees. The curves diverge early, which can be a confounding tell, though later flattening is hard to square with a fixed hidden bias.
What to watch
Randomized trials. Denmark is already running a Shingrix trial on dementia and heart outcomes; GSK has a dementia-focused trial in Finland. Whether a second dose restores the early-years signal. And whether public-health agencies treat a cardiac echo as a bonus of a shot people should already get for shingles, rather than a reason to re-pitch the vaccine.
Sources
- Corsi-Zuelli F. et al. Recombinant shingles vaccination and the risk of cardiovascular events. Nature Medicine, published 26 August 2026. https://doi.org/10.1038/s41591-026-04606-0
- NIHR Oxford Health BRC. New shingles vaccine linked to lower risk of coronary heart disease, stroke and heart failure. https://oxfordhealthbrc.nihr.ac.uk/new-shingles-vaccine-linked-to-lower-risk-of-coronary-heart-disease-stroke-and-heart-failure-major-study-indicates/
